• Wednesday, May 1, 2024 @ 12:00 am

Positive results of Study 008A were reported of evenamide in schizophrenia patients who respond inadequately to current antipsychotics. Substantial equity upside to be unlocked upon a partnering deal with a major CNS player and the start of Study 017 in TRS patients.

Key catalysts include:

  1. Release of more detailed “Study 008A” data (coming weeks)
  2. Partnering evenamide with a major CNS player (before starting “Study 017”)
  3. Start pivotal “Study 017” trial of evenamide in TRS (Q4 2024)

Newron Flash Update

You may also be interested in